Sengupta N - Search Results

1

Simulation Model of Ibrutinib in Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL).

Peng S, Sorensen S, Pan F, Dorman E, Sun S, Van Sanden S, Sengupta N, Gaudig M. Peng S, et al. Among authors: sengupta n. Value Health. 2014 Nov;17(7):A620. doi: 10.1016/j.jval.2014.08.2196. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202180 Free article. No abstract available.

2

Systematic Review of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Clinical Trials: Implications for Decision Modeling.

Sorensen S, Dorman E, Xu Y, Sallum R, Pan F, Szatkowski A, Gaudig M, Sengupta N. Sorensen S, et al. Among authors: sengupta n. Value Health. 2014 Nov;17(7):A615-6. doi: 10.1016/j.jval.2014.08.2168. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202152 Free article. No abstract available.

3

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Sallum R, Dorman E, Xu Y, Tran-Kerr K, O'Donnell M, Sorensen S, Szatkowski A, Sengupta N, Gaudig M. Sallum R, et al. Among authors: sengupta n. Value Health. 2014 Nov;17(7):A616. doi: 10.1016/j.jval.2014.08.2172. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202158 Free article. No abstract available.

4

Simulation Model of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) With Prior Treatment.

Pan F, Peng S, Sorensen S, Dorman E, Sun S, Gaudig M, Sengupta N. Pan F, et al. Among authors: sengupta n. Value Health. 2014 Nov;17(7):A620-1. doi: 10.1016/j.jval.2014.08.2198. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202182 Free article. No abstract available.

5

Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL), Using Matching Adjusted Indirect Comparison.

Tongbram V, Sengupta N, Gaudig M, Sidhu M, Exuzides A, Colby C, Sanden SV, McGovern A. Tongbram V, et al. Among authors: sengupta n. Value Health. 2014 Nov;17(7):A614-5. doi: 10.1016/j.jval.2014.08.2163. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202151 Free article. No abstract available.

6

Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Sorensen S, Wildgust M, Sengupta N, Trambitas C, Diels J, van Sanden S, Xu Y, Dorman E. Sorensen S, et al. Among authors: sengupta n. Clin Ther. 2017 Jan;39(1):178-189.e5. doi: 10.1016/j.clinthera.2016.12.001. Epub 2017 Jan 3. Clin Ther. 2017. PMID: 28062113 Review.

7

Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.

Cramer P, Fraser G, Santucci-Silva R, Grosicki S, Dilhuydy MS, Janssens A, Loscertales J, Rule S, Goy A, Traina S, Chan EKH, Diels J, Sengupta N, Mahler M, Salman M, Howes A, Chanan-Khan A. Cramer P, et al. Among authors: sengupta n. Leuk Lymphoma. 2018 Sep;59(9):2075-2084. doi: 10.1080/10428194.2017.1416364. Epub 2018 Jan 3. Leuk Lymphoma. 2018. PMID: 29295653 Clinical Trial.

8

A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease.

Csanadi M, Agh T, Tordai A, Webb T, Jeyakumaran D, Sengupta N, Schain F, Mattsson J. Csanadi M, et al. Among authors: sengupta n. Expert Rev Hematol. 2019 May;12(5):311-323. doi: 10.1080/17474086.2019.1605288. Epub 2019 Apr 19. Expert Rev Hematol. 2019. PMID: 30955381

9

Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status.

Agh T, Csanadi M, Voko Z, Webb T, Jeyakumaran D, Trudeau J, Sengupta N, Schain F, Mattsson J. Agh T, et al. Among authors: sengupta n. Expert Rev Hematol. 2019 May;12(5):295-309. doi: 10.1080/17474086.2019.1602036. Epub 2019 Apr 14. Expert Rev Hematol. 2019. PMID: 30925855

10

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.

Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Torrance GW, et al. Among authors: sengupta n. Rheumatology (Oxford). 2004 Jun;43(6):712-8. doi: 10.1093/rheumatology/keh153. Epub 2004 Mar 23. Rheumatology (Oxford). 2004. PMID: 15039494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters